Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells

International Journal of Oncology

Volumn 13, Issue 2, 1998, Pages 397-405

  Gazitt, Yair ^a   Fey, Valerie ^a   Thomas, Charles ^b   Alvarez, Robert ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

bax; bcl 2; bclx; Drug resistance; Myeloma

Indexed keywords

DEXAMETHASONE; DIMETHYL SULFOXIDE; GLUCOCORTICOID; MELPHALAN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTO ONCOGENE;

EID: 0031847918     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.13.2.397     Document Type: Article

References (46)

1. Barlogie B, Smith L and Alexanian R: Effective treatment of multiple myeloma refractory to alkylating agents. N Engl J Med 310: 1353-1356, 1984.
2. Barlogie B, Hall R, Zander A, Dicke K and Alexanian R: High dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 67: 1298-1303, 1986.
3. Gregory W, Richards M and Malpas J: Combination chemotherapy versus melphalan and prednisone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10: 336-340, 1992.
4. Blade J, San Miguel JE, Alcala A, Maldonado J, Sanz MA, Conde JG, Moro MJ, Alonso C, Besalduch J, Zubizarreta A, Besses C, Brito GG, Martin JH, Calvo JF, Rubio D, Ortega F, Jimenez R, Colominas P, Faura MV, Font L, Tortosa J, Dimingo A, Fontanillas M, Rozman C and Estape J: Alternating combination VCMP/VBAP chemotherapy vs. melphalan/ prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 11: 1165-1171, 1993.
5. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM and Dixon DO: Alternating combination chemotherapy improves survival in multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol 1: 453-461, 1983.
6. Alexanian R, Dimopoulos MA, Delasalle K and Barlogie B: Primary dexamethasone treatment for multiple myeloma. Blood 80: 887-892, 1992.
7. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, Dreyfus F, Troussard X, Brechignian S, Mariette X and Bruet JC: High dose therapy and autologous blood stem cell transplantation in multiple myeloma. Blood 82: 2005-2010, 1993.
8. Tricot G, Jagannath S, Vesole DH, Crowley J and Barlogie B: Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 16: 7-11, 1995.
9. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JE, Casassus P, Maisoneuve H, Facon T, Ifrah N, Payen C and Bataille R: A prospective randomized trial of autologous transplantation and chemotherapy in multiple myeloma. N Engl J Med 335: 91-97, 1996.
10. Urashima M, Teoh G, Chauhan D, Hoshi Y, Ogata A, Treon SP, Schlossman RL and Anderson KC: Interleukin-6 overcomes p21 upregulation and G1 growth arrest induced by dexamethasone and interferon gamma in multiple myeloma cells. Blood 90: 279-289, 1997.
11. Chen Y, Feng X-X and Schilder L: Effect of vincristine, adriamycin, and glucocorticosteroids on myeloma cells in vitro. Acta Hematol 89: 61-66, 1993.
12. Tian E and Gazitt Y: The role of P53, bel and bax in dexamethasone-induced apoptosis in myeloma cell lines. Int J Oncol 8: 719-726, 1996.
13. Hu W-X and Gazitt Y: Bcl-2 plays a major role in resistance to apoptosis in myeloma cells. Int J Oncol 9: 375-381, 1996.
14. Tian E, Hu W-X and Gazitt Y: Bcl-2 plays a critical role in growth and in spontaneous or induced apoptosis in myeloma cell lines: a study with inducible bcl-2 transfection constructs. Int J Oncol 9: 165-169, 1996.
15. Hardin J, Macleod S, Grigorieva I, Chang R, Barlogie B, Xiao H and Epstein J: Interleukin-6 prevents dexamethasone induced myeloma cell death. Blood 84: 3063-3070, 1994.
16. Xu F, Gardner A, Tu Y, Michel P, Prager D and Lichtenstein A: Multiple myeloma cells are protected against dexamethasone-induced insulin-like growth factors. Br J Hematol 97: 429-440, 1997.
17. Mulcahy RT, Bailey HH and Gipp JJ: Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 34: 67-71, 1994.
18. Bezwoda WR and Pu QQ: In vitro assessment of melphalan induced cytotoxicity and interstrand-DNA cross-links in lymphocytes from patients with lymphoproliferative disorders: correlation and mechanism of alkylator resistance in vitro and in vivo. Int J Oncol 10: 1061-1068, 1997.
19. Waxman DJ: Glutathione S-transferase: role in alkylating agent resistance and possible target for modulation chemotherapy - A review. Cancer Res 50: 6449-6454, 1990.
20. Dalton WS and Salmon SE: Drug resistance in myeloma: Mechanisms and approaches for circumvention. Hematol Oncol Clin North Am 6: 383-393, 1992.
21. Boccadoro M, Palumbo A, Argentino C, Dominietto A, Frieri R, Avisati G, Comotti B, Luta VM, Libcrati M, Marmot F, Musto P, Tribalto M and Pileri A: Conventional induction treatments do not influence overall survival in multiple myeloma. Br J Hematol 96: 333-337, 1997.
22. Gazitt Y and Reading CL: Autologous transplantation with tumor-free graft: a model for multiple myeloma patients. Leuk Lymphoma 23: 203-212, 1996.
23. Krajevski S, Tanaka S, Takayama S, Schibler MJ, Fenton W and Reed JC: Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane. Cancer Res 53: 4701-4714, 1993.
24. Korsmeyer SJ: Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80: 879-886, 1992.
25. Yang E and Korsmeyer SJ: Molecular thanatopsis: a discourse on bcl-2 family of proteins. Blood 88: 386-401, 1996.
26. Reed JC, Kitada S and Miyashita T: Regulation of chemoresistance by the bcl-2 oncoprotein in non-Hodgkin's lymphoma and lymphocytic leukemia cell lines. Ann Oncol 5: s61-s65, 1994.
27. Tsujimoto Y, Crossman J, Jaffe E and Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science 228: 1440-1442, 1985.
28. Hermine O, Haioun C, Lepage E, D'Agay M-F, Briere J, Lavignac C, Fillet G, Salles G, Marplleau J-P, Diebold J, Reyes F and Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87: 265-272, 1996.
29. Robertson LE, Plunkett W, McConnell K, Kcating MJ and McDonnell JT: Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10: 456-459, 1996.
30. Ibrado AM, Huang Y, Liu L and Bhalla K: Overexpression of bcl-2 or bclx inhibits ARA-C induced CPP32/Yama protease activity of human acute myelogenous leukemia HL-60 cells. Cancer Res 56: 4743-4748, 1996.
31. Pettersson M, Jernberg-Wiklund H, Larsson LG, Sundstrom C, Givol I, Tsujimoto Y and Nilson K: Expression of bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 79: 495-502, 1992.
32. Gazitt Y, Lavia MF and Erdos GW: Regulation of cell growth and apoptosis in synchronized AGF cells: involvement of oncogenes and cell cycle regulatory proteins. Int J Oncol 3: 489-496, 1993.
33. Gazitt Y and Erdos GW: Fluctuation and ultrastructural localization of oncogenes and cell cycle regulatory proteins during growth and apoptosis of AGF cells. Cancer Res 54: 950-956, 1994.
34. Teoh G, Urashima M, Ogata A, Chauhan D, Decaprio JA, Treon SP, Schlossman RL and Anderson CK: MDM2 protein overexpression promotes proliferation and survival of multiple myeloma cells. Blood 90: 1982-1992, 1997.
35. Ishikawa H, Tanaka H, Iwato K, Tanabe O, Asaoku H, Nobuyoshi M, Yamamoto I, Kawano M and Kuramoto A: Effect of glucocorticoids on the biological activities of myeloma cells: inhibition of IL-1ß-induced bone resorption. Blood 75: 715-720, 1990.
36. Gazitt Y and Hu W-X: Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: a study with cell line overexpressing bcl-2 and with bcl-2 transfected cell lines. Int J Oncol 12: 211-220, 1998.
37. Sciola L, Spano A, Monaco G, Manconi V, Pippia P and Barni S: Dexamethasone apoptosis induction and glucocorticoid receptor levels in cultured normal and neoplastic cells. Int J Oncol 11: 999-1005, 1997.
38. Fernberg J, Lewensohn R and Skog S: Interphase cell cycle death as related to the cell cycle of melphalan-treated human myeloma cells. Med Oncol Tumor Pharmacol 8: 63-67, 1991.
39. Bosanquet AG and Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 335-341, 1982.
40. Wu GS and El-Deiry WS: Apoptotic death of tumor cells correlates with chemosensitivity independent of p53. Clin Cancer Res 2: 623-633, 1996.
41. Hansson J, Lewensohn R, Ringborg U and Nilsson B: Formation and removal of DNA cross-link by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47: 2631-2637, 1987.
42. Batist G, Torres-Garcia S, Demuys JM, Greene D, Lehnert S, Rochon M and Panaski L: Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. Mol Pharmacol 36: 224-230, 1989.
43. Redwood WR and Colvin M: Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 40: 1144-1149, 1980.
44. Friedman HS, Skapek SX, Colvin OM, Elion GB, Blum MR, Savina PM, Hilton J, Schold SC, Kurtzberg JJ and Binger DD: Melphalan transport, glutathione levels, and glutathione S-transferase activity in human medulloblastoma. Cancer Res 48: 5397-5402, 1988.
45. Bellamy WT, Dalton WS, Gleason MC, Grogan TM and Trent JM: Development and characterization of a melphalan resistant human multiple myeloma cell line. Cancer Res 51: 995-1002, 1991.
46. Petrini M, Di Simone D, Favati A, Matth L, Valentini P and Grassi B: GST-π and P-170 co-expression in multiple myeloma. Br J Haematol 90: 393-397, 1995.